Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2002 2
2003 5
2004 5
2005 3
2006 8
2007 7
2008 8
2009 14
2010 14
2011 9
2012 24
2013 23
2014 23
2015 20
2016 28
2017 32
2018 35
2019 43
2020 51
2021 55
2022 65
2023 84
2024 95
2025 97
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

704 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. Among authors: wu h. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, de Bono JS. Antonarakis ES, et al. Among authors: wu h. J Clin Oncol. 2020 Feb 10;38(5):395-405. doi: 10.1200/JCO.19.01638. Epub 2019 Nov 27. J Clin Oncol. 2020. PMID: 31774688 Free PMC article. Clinical Trial.
Charting brain morphology in international healthy and neurological populations.
Zhuo Z, Chai L, Wang Y, Gao P, Xu X, Ai L, Ao F, Bai Y, Bai Y, Cole JH, Bao H, Cai Q, Cao J, Chen F, Chen F, Chen K, Chen Y, Cheng D, Cui Z, Dai H, Deng D, Du Y, Fan G, Fu Y, Gao Z, Gou L, Guo C, Guo M, Guo Y, Han X, He H, Hou Y, Hu B, Hu J, Huang CC, Huang P, Lei J, Li HJ, Li J, Li J, Li K, Li S, Li W, Li X, Li Y, Li Y, Li Y, Li Y, Li Y, Liang P, Liao H, Lin CP, Liu J, Liu J, Liu W, Liu Y, Lu S, Luo J, Luo Y, Lui S, Ma H, Mao N, Meng L, Meng L, Qian Y, Qiu J, Rong M, Shao J, Shen Q, Shi Y, Shu Z, Sun J, Tian D, Tu Y, Wang F, Wang J, Wang J, Wang W, Wang X, Wang Y, Wang Y, Wang Z, Weng J, Wu F, Wu Y, Wu Y, Wu H, Xia X, Xu C, Xu J, Xu J, Xu R, Xu S, Yan P, Yang R, Yin S, Yin X, Yin Y, Yu R, Yuan Z, Zhang F, Zhang H, Zhang J, Zhang N, Zhang R, Zhang T, Zhang Y, Zhang Z, Zhang Z, Zhang Z, Zhao J, Zhao L, Zhao X, Zhao X, Zhao X, Zhe X, Zhou F, Zhu J, Zhu L, Li K, Duan X, Duan Y, Zuo XN, Liu Y. Zhuo Z, et al. Among authors: wu h. Nat Neurosci. 2026 Feb;29(2):420-434. doi: 10.1038/s41593-025-02144-5. Epub 2025 Dec 29. Nat Neurosci. 2026. PMID: 41461930
2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS.
Zhou J, Yin L, Wei X, Zhang S, Song Y, Luo B, Li J, Qian L, Cui L, Chen W, Wen C, Peng Y, Chen Q, Lu M, Chen M, Wu R, Zhou W, Xue E, Li Y, Yang L, Mi C, Zhang R, Wu G, Du G, Huang D, Zhan W; Superficial Organ and Vascular Ultrasound Group of the Society of Ultrasound in Medicine of the Chinese Medical Association; Chinese Artificial Intelligence Alliance for Thyroid and Breast Ultrasound. Zhou J, et al. Endocrine. 2020 Nov;70(2):256-279. doi: 10.1007/s12020-020-02441-y. Epub 2020 Aug 21. Endocrine. 2020. PMID: 32827126
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK. Tabernero J, et al. Among authors: wu h. Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9. Epub 2018 Sep 11. Lancet Oncol. 2018. PMID: 30217672 Clinical Trial.
704 results